Tuesday, May 6, 2014
ALEMBIC PHARMACEUTICALS - RESULTS -Q4 & FY 14 - NET SALES UP 23% YoY; NET PROFIT UP 40% YoY
ALEMBIC PHARMACEUTICALS LTD
RESULTS FOR Q4 & FY 14
HIGHLIGHTS FOR Q4 FY14
Ø Net sales up by 23% to Rs.456.28 Cr against Rs.378 Cr in Q4 FY 13.
Ø Profit from Operations stands at Rs.91.29 cr; against Rs.65.58 cr in Q4 FY 13.
Ø Profits Before Tax up by 46% to Rs.81 Cr against Rs.58 Cr in Q4 FY 13
Ø Net Profit after Tax up by 40% to Rs.61.3 cr against Rs.43.7 cr in Q4 FY 13.
Ø EBITDA margins is 19.6% at rs.91.3.cr against Rs.65.6 Cr in Q4 FY 13.
Ø Paid up Equity stands at Rs.37.70 Cr.
Ø Basic EPS stands at Rs.3.25 against a Face Value of Rs.2. – against Rs.3.5 in previous quarter and Rs.2.32 in Q4 FY 13.
Year Ended 31st March 2014
Ø Net Sales up by 22% to Rs.1868.4 cr against Rs.1526 cr last year.
Ø Profit from Operations stands at Rs.358 cr against Rs.252 cr Last Year.
Ø Profit Before Tax up by 51% to Rs.310.6 Cr against Rs.206.4 Cr last year.
Ø Net Profit After Tax up by 43% to Rs.235.5 Cr against Rs.165.3 cr last year.
Ø EBITDA margins is 19.2% at Rs.357.7 Cr against 16.5% at rs.252 cr last year.
Ø Basic EPS stands at Rs.12.49 against Rs.8.77 cr last year (on a FV of Rs.2)
Ø The Board has recommended Dividend at Rs.3 per share or 150% for FY 14 against Rs.2.50 or 125% per share last year.
Ø The India Branded Formulations Business posted Sales of Rs.199.5 Cr against Rs.175.3 Cr with a 14% growth over Q4 FY 13.
Ø The India Branded Formulations Business posted Sales for Year ended 31-03-2014 of Rs.850.6 Cr against Rs.748.4 Cr with a 14% growth over the previous year.
Ø As per ORG IMS, Alembic has market share of 1.73% (MAT-Mar 14). Gestofit has featured as company’s 5th brand in top 300 Brands list of IMS-ORG.
Ø Specialty and Acute segments grew by 17% and -3% respectively in current years (MAT – Mar 14) versus Industry average growth rate of 11% and 3% respectively.
Ø International Generics formulation posted growth of 76% and posted sales of Rs.136.7 crores against Rs.77.7 Cr over Q4 FY 13.
Ø International Generics formulation posted Sales for the year FY 14 of Rs.468.4 crores against Rs.235.8 Cr with a 99% Growth over FY 13.
Ø During Q4, 1 ANDA application and for the year 4 ANDA applications were filed taking cumulative ANDA filings of the company to 61.
Ø During the quarter, 1 ANDA approval and for the year 8 ANDA approvals were received taking cumulative ANDA/NDA approvals to 32 (including 4 tentative approvals). During the quarter, 2 DMF applications and for the year 6 DMF applications were filed taking cumulative DMF filings of the company to 66.
About Alembic Pharma
A vertically integrated R&D Pharma co. Manufactures and markets Generic Pharma products all over the world. Its state of the Art research & Manufacturing facilities are approved by US FDA and other regulatory authorities. Alembic’s brands, marketed through a marketing team of over 4000 are well recognized .
Alembic Pharma has been progressing well quarter after quarter. Its R&D is strong and is producing Generic Pharma Products regularly. It is therefore a good BUY for medium / Long term Investors.
* * * E N D * * *